Chow W, Frankel P, Ruel C, et al. - In this single-arm, multicenter, phase 2 study, researchers appraised the safety and antitumor activity of pazopanib in patients with unresectable or metastatic conventional chondrosarcoma. They administered pazopanib at 800 mg once daily for 28-day cycles to 47 patients who had conventional chondrosarcoma of any grade with measurable tumors that were unresectable or metastatic. At 16 weeks, they observed the disease control rate (DCR) of 43%, which was superior to the null hypothesis rate of 30%, but with the 2-sided P value (exact test) of .09 (1-sided P = .045). The patients had the median overall survival of 17.6 months, and the median progression-free survival of 7.9 months. They infrequently encountered grade 3 or higher adverse events; hypertension (26%) and elevated alanine aminotransferase (9%) were most common. This work thereby yielded evidence supporting the positive drug activity for pazopanib in conventional chondrosarcoma.